Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.67 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43922 | 1.00 | TSHR (0.67) | TSHRLOXL2LMNAALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL31687554 | 0.98 | TSHR (0.65) | TSHRLOXL2LMNAALDH1A1NPC1 | |
| Bromide SCHEMBL31513711 | 0.98 | TSHR (0.65) | TSHRLOXL2LMNAALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL1017929 | 0.98 | TSHR (0.65) | TSHRLOXL2LMNAALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL1970066 | 0.98 | TSHR (0.65) | TSHRLOXL2LMNAALDH1A1NPC1 | |
| Trimethylammonium SCHEMBL27367476 | 0.93 | TSHR (0.59) | TSHRLOXL2LMNAALDH1A1NPC1 | |
| Nitrobenzene SCHEMBL11745249 | 0.86 | LOXL2 (0.73) | TSHRLOXL2LMNAALDH1A1NPC1 | |
| SCHEMBL12209734 | 0.85 | FFAR1 (0.56) | TSHRLOXL2LMNAALDH1A1NPC1 | |
| SCHEMBL12209750 | 0.85 | NFE2L2 (0.66) | TSHRLOXL2LMNAALDH1A1NPC1 | |
| SCHEMBL6545015 | 0.85 | TSHR (0.62) | TSHRLOXL2LMNAALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| WO-2024220708-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | GANDEEVA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-117813293-A | Urea derivatives useful for the treatment of cancer | 蝎子疗法股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ORIGIANT PHARMACEUTICAL CO., LTD (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-4212525-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Origiant Pharmaceutical Co., Ltd (CN) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | RIPK1, RIPK3, RIPK2 | TSHR 2487/4885LOXL2 3900/4885LMNA 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.